Carl Icahn shares common ground with the FTC, which argued that Illumina’s acquisition of cancer test developer Grail would stifle competition and innovation.
You are here: Home / Carl Icahn says Illumina’s appeal of FTC order to divest Grail is ‘an almost impossible battle’